Allogene Therapeutics Stock Target Price
| ALLO Stock | USD 2.69 0.10 3.86% |
Allogene Therapeutics fundamentals help investors to digest information that contributes to Allogene Therapeutics' financial success or failures. It also enables traders to predict the movement of Allogene Stock. The fundamental analysis module provides a way to measure Allogene Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Allogene Therapeutics stock.
Allogene | Target Price |
Allogene Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Allogene Therapeutics from analyzing Allogene Therapeutics' financial statements. These drivers represent accounts that assess Allogene Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Allogene Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.6B | 3.0B | 2.0B | 900.4M | 503.8M | 478.6M | |
| Enterprise Value | 2.1B | 2.1B | 1.3B | 419.0M | 515.7M | 489.9M |
Allogene Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Allogene Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Allogene Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Allogene Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 165.46 M | ||||
| Shares Outstanding | 208.78 M | ||||
| Shares Owned By Insiders | 17.06 % | ||||
| Shares Owned By Institutions | 64.56 % | ||||
| Number Of Shares Shorted | 33.87 M | ||||
| Price To Earning | (3.30) X | ||||
| Price To Book | 1.25 X | ||||
| Price To Sales | 6,764 X | ||||
| Revenue | 95 K | ||||
| Gross Profit | 243 K | ||||
| EBITDA | (287.05 M) | ||||
| Net Income | (327.26 M) | ||||
| Cash And Equivalents | 490.49 M | ||||
| Cash Per Share | 3.41 X | ||||
| Total Debt | 95.12 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 11.42 X | ||||
| Book Value Per Share | 2.71 X | ||||
| Cash Flow From Operations | (237.73 M) | ||||
| Short Ratio | 18.04 X | ||||
| Earnings Per Share | (1.78) X | ||||
| Price To Earnings To Growth | (4.18) X | ||||
| Target Price | 11.55 | ||||
| Number Of Employees | 232 | ||||
| Beta | 0.9 | ||||
| Market Capitalization | 555.37 M | ||||
| Total Asset | 642.84 M | ||||
| Retained Earnings | (1.56 B) | ||||
| Working Capital | 422.04 M | ||||
| Current Asset | 418.72 M | ||||
| Current Liabilities | 26.36 M | ||||
| Net Asset | 642.84 M |
About Allogene Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Allogene Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Allogene Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Allogene Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Allogene Therapeutics Piotroski F Score and Allogene Therapeutics Altman Z Score analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Allogene Stock analysis
When running Allogene Therapeutics' price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.27) | Return On Assets (0.27) | Return On Equity (0.55) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.